RxDoctor Payments DataLook up a doctor →

Satish Modi, MD

Ophthalmology · Poughkeepsie, NYNPI 1316957350

Payments from drug & device makers

$764,785in general payments, 2019–2025

Across 486 payments — averaging $1573.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$514K
  • Rxsight Inc$116K
  • Alcon$79K
  • Bausch & Lomb Americas Inc.$31K
  • Ocular Therapeutix, Inc.$10K
  • AbbVie$9K
  • plus $6K from 31 others
$1,645,765in research payments, 2019–2025

Across 1,139 payments — averaging $1444.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$1.5M
  • AbbVie$106K

What the payments were for

  • Consulting fees$172,24073%
  • Speaking & faculty fees$35,46615%
  • Travel & lodging$16,6587%
  • Food & beverage$11,6275%
  • Education$1,3441%
  • Gifts$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$764,785 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$420,436
Medicare patients
719
Services billed
2,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost57$36,180
RestasisCyclosporine11$20,230
Travoprost44$9,375
Timolol Maleate48$8,490
Prednisolone Acetate288$7,873
CombiganBrimonidine Tartrate/Timolol11$6,580
Ketorolac Tromethamine295$4,703
RocklatanNetarsudil Mesylat/Latanoprost11$4,215
Latanoprost121$2,466
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$2,390
Brimonidine Tartrate19$2,388
Brinzolamide11$2,339
Ciprofloxacin Hcl219$2,068
Dorzolamide Hcl35$1,151
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat60$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$9,465$62,99079 claims
Aerie Pharmaceuticals, Inc.Rocklatan$200$4,21511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →